http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105030764-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 |
| filingDate | 2015-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105030764-B |
| titleOfInvention | Application of the andrographolidume derivative in preparation treatment inflammatory bowel medicine |
| abstract | The present invention provides a kind of application of andrographolidume derivative in preparation treatment inflammatory bowel disease.Andrographolidume derivative AL-1 treats the mechanism of ulcerative colitis and removes free radical, inhibits the activation of NF- κ B signal access and the expression of COX-2, activates the expression of PPAR- γ, and then prevent the transcript and expression of inflammation-related gene, improves inflammatory conditions.The AL-1 can be used as the drug for the treatment of inflammatory bowel disease, and various dosage forms can be made with available pharmaceutical carrier. |
| priorityDate | 2015-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 167.